Kanwarpal S. Kahlon, MD, is an associate clinical professor of medicine at the UCLA School of Medicine.

Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia

“Maybe [generic eltrombopag is] a treatment option that [hematologists] will feel more comfortable and confident reaching for because they know they’ll be able to get it for their patients.”

Kanwarpal S. Kahlon, MD, an associate clinical professor of medicine at the UCLA School of Medicine, discussed the significance of the availability of generic eltrombopag (Promacta) for patients with severe aplastic anemia and immune thrombocytopenia.

On May 14, 2025, generic, AB-rated formulations of eltrombopag 

 for the treatment of patients with severe aplastic anemia who have insufficient response to immunosuppressive therapy; the treatment of patients at least 1 year of age with persistent or chronic immune thrombocytopenia who have insufficient response to other treatments and who have an increased risk of bleeding; and the management of thrombocytopenia in patients with chronic hepatitis C whose clinical condition limits or prevents initiation or maintenance with interferon-based therapy. Notably, the generic form of this agent is available as both an oral suspension and a tablet.

The availability of generic eltrombopag expands access to a drug that was previously limited for some patients due to barriers like a lack of insurance coverage or high out-of-pocket costs, Kahlon explained. Anecdotally, the financial burden associated with accessing certain therapies varies widely, he noted. The introduction of the generic form of this agent with potentially competitive pricing may enhance its accessibility and affordability, thereby increasing its use in clinical practice, according to Kahlon.

Hematologists may now feel more confident prescribing this agent, knowing that it is likely to be accessible to more of their patients, Kahlon stated. This situation may mirror what has been observed with other novel therapies that have become more readily used once generic formulations or biosimilars entered the market, he said. Ultimately, this increased access will benefit patients with aplastic anemia and immune thrombocytopenia, which are notably chronic diseases, he concluded.

Videos

Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Camber Pharmaceuticals, we spoke with Kanwarpal S. Kahlon, MD, an associate clinical professor of medicine at the UCLA School of Medicine.

In our exclusive interview, Dr Kahlon discussed the significance of the commercial availability of the generic, AB-rated formulations of eltrombopag (Promacta), a bioequivalent medication for the treatment of select patients with severe aplastic anemia and immune thrombocytopenia. He noted how the biosimilar is expected to reduce costs and improve the accessibility of this treatment, potentially enhancing patient adherence. He also explained how it is available in both oral suspension and tablet formulations and that it is well tolerated, with a safety profile similar to that of the original drug.

That’s all we have for today! Thank you for listening to this episode of 

 Camber Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Kahlon discusses the availability of the generic formulations of eltrombopag for patients with aplastic anemia and immune thrombocytopenia.

Kanwarpal S. Kahlon, MD

Articles

Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia

Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD